Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > CPH: Debt-Free since October 30, 2020

<< Previous

Bullboard Posts

Next >>

Post by stockfyon Jan 20, 2021 5:33pm

244 Views

Post# 32340417

CPH: Debt-Free since October 30, 2020

CPH has been debt free since October 30, 2020, facts below:

"The Company generated $5.5 million in cash from operating activities during the nine-month period ended September 30, 2020 . As of September 30, 2020 , the Company had cash of $4.7 million and $1.7 million drawn on the credit facility. The Company's credit facility has been paid off as at October 30, 2020 ."

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)